Action PULM PULMATRIX, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Pulmatrix, Inc.

Actions

PULM

US74584P3010

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 29/04/2024 		Varia. 5j. Varia. 1 janv.
1,9 USD -6,86 % Graphique intraday de Pulmatrix, Inc. -5,71 % +2,15 %
28/03 Pulmatrix, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI
13/03 Pulmatrix, Inc. approuve la cessation d'emploi de Margaret Wasilewski à titre de chef de la direction médicale CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
Pulmatrix Explores Strategic Alternatives
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Sector Update: Health Care Stocks Easing Late Tuesday
Sector Update: Health Care Stocks Lower Tuesday Afternoon
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PULM
  4. Actualités Pulmatrix, Inc.
  5. Autres langues